api
-
apceth, Indivumed to develop biomarker platform for targeted cellular therapies
apceth and Indivumed have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
api | 27 March 2012
-
Major IT trends shaping life sciences in 2012
Three IT trends will shape the life sciences in 2012, according to an analysis by SAFE-BioPharma Association. They are the expanded use of standards-based interoperable digital identities, cloud computing in clinical trials, and the use of electronic trial master files for clinical trial management.
api | 23 March 2012
-
New data presented on phase 3 trial Of ELIQUIS (apixaban) in the prevention of venous thromboembolism in patients with acute medical illness
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30.
api | 15 November 2011
-
Novartis receives approval in Japan for two innovative therapies
Approvals demonstrate ongoing Novartis commitment to bringing innovative treatments to patients in Japan.
api | 27 September 2011
-
Evitria achieves 1 gram per liter in rapid protein production
evitria SA has achieved a breakthrough in transient gene expression. Using Life Technologies’ Invitrogen FreeStyle CHO-S Cells, evitria scientists succeeded in obtaining titers exceeding 1 gram per liter in transient. evitria’s rapid protein…
api | 02 March 2011
-
Apixaban demonstrates statistical superiority to enoxaparin
BMS and Pfizer 's ADVANCE-3 study results, published in The New England Journal of Medicine, showed apixaban was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing electiv…
api | 02 March 2011
-
API China, Interphex China Autumn 2010: Bringing the world closer
With tens of thousands of delegates visiting the exhibition, this autumn edition proves to be the proverbial bridge connecting foreign and local businesses. LEE KOK LEONG reports from Suzhou.
api | 01 January 2011
-
Growth of cancer targeted therapies and immunotherapies
Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst Datamonitor. Over the l…
api | 01 October 2010
-
Agilent: 1260 Infinity LC offers rapid resolution power
Agilent Technologies introduces the 1200 Infinity Series for analytical HPLC and UHPLC. The series includes 1220 Infinity LC, 1260 Infinity LC and 1290 Infinity LC. The 1260 Infinity LC offers more rapid resolution power, pushing RRLC performanc…
api | 01 August 2010
-
UBC secures additional US$150m from capital markets
United BioSource Corporation (UBC) announced that it had secured a new line of credit that provides the company with up to US$150m in additional financing for acquisitions and other significant growth investments. Wells Fargo, PNC Bank, Capital One …
api | 09 July 2010
